Body Recomposition Peptide Stack Research — GLP-1 + GHRH Mechanism and Dose Math

Body recomposition — losing fat while preserving or gaining lean mass — is the single most-asked-about endpoint in peptide research consultation. The reason it's hard: GLP-1 receptor agonists drive impressive total weight loss, but published meta-analyses consistently show that 25-40% of the lost weight is lean mass. The stacking case for pairing GLP-1 with GHRH analogues like Tesamorelin rests directly on addressing that lean-mass loss problem. This guide walks the mechanism, the dose math, and what the published literature does and doesn't support — framed for UAE peptide researchers ordering through REVIVE LAB.

1. The lean-mass-loss problem with GLP-1 monotherapy

GLP-1 RA monotherapy works. Wilding 2021 (STEP-1, semaglutide) reported 14.9% mean total weight loss at 68 weeks. Jastreboff 2023 (retatrutide phase 2) reported 24.2% at 48 weeks. These are unprecedented numbers for non-surgical interventions. But DEXA-based body-composition substudies in the GLP-1 RA literature consistently show that 25-40% of that lost weight is lean mass — primarily skeletal muscle.

Two factors drive the lean-mass loss:

• Caloric deficit per se. Any sustained caloric deficit produces some lean-mass loss, regardless of mechanism. GLP-1 RAs drive aggressive deficits via appetite suppression, so the absolute lean-mass loss is large.
• Protein intake collapse. Reduced appetite drives reduced total food intake, including protein. Patients on GLP-1 RAs commonly under-consume protein by 30-50% versus baseline — well below the 1.2-1.6 g/kg/day intake associated with lean-mass preservation during caloric deficit.

2. The GHRH mechanism case for adding Tesamorelin

Tesamorelin is a stabilised GHRH analogue. It drives pulsatile growth hormone release from the pituitary, producing an endogenous GH pulse profile that approximates youthful physiology more closely than exogenous GH dosing. The Falutz 2010 JCEM trial (the FDA-approval study for HIV lipodystrophy) demonstrated 15% visceral adipose tissue (VAT) reduction over 26 weeks at 2 mg/day SC bedtime. The Stanley 2014 JAMA replication confirmed the effect.

The mechanistic relevance to body recomposition has three parts:

• VAT-preferential fat loss. GH pulses drive lipolysis preferentially in visceral adipose. This is exactly the fat depot most metabolically detrimental and most resistant to GLP-1-driven loss.
• IGF-1 axis support. Endogenous GH pulses elevate IGF-1, which supports muscle protein synthesis. This is the lean-mass-preservation arm of the stack rationale.
• Pulsatile vs continuous. Tesamorelin produces pulsatile GH release (physiological), unlike exogenous GH which produces sustained supraphysiological levels (associated with insulin resistance, edema, and side-effect burden).

3. The published dose pairing

There is no published RCT testing the combined Retatrutide + Tesamorelin stack. The dose-pairing recommendations cited across research-protocol discussions extrapolate from the two independent monotherapy datasets:

The two peptides have no documented pharmacokinetic interaction. Same-day administration is fine. The bedtime Tesamorelin dose aligns with the natural GH pulse window (deep sleep, roughly 11 PM-3 AM) — this timing is important enough that Falutz 2010 explicitly specified bedtime dosing.

4. Vial math — what to order for an 8-week protocol

Building the order list for an 8-week titration-to-mid-dose protocol:

5. Protein, training, and the deficit-shape problem

Peptide stack alone doesn't produce body recomposition. The published lean-mass-preservation data on GH-axis peptides requires the substrate (dietary protein) and the stimulus (resistance training). Researchers running protocols without those two inputs see weight loss with lean-mass loss, regardless of stack composition.

• Protein floor: 1.6-2.2 g/kg/day of high-quality protein is the meta-analytic floor for lean-mass preservation during caloric deficit. GLP-1 appetite suppression makes hitting this hard — protein shakes and protein-forward meal structure are typically required.
• Resistance training: 2-4 sessions/week of progressive resistance training provides the muscle protein synthesis stimulus that combines with GHRH-driven IGF-1 to defend lean mass.
• Deficit size: Aggressive caloric deficits (>500 kcal/day) amplify lean-mass loss regardless of pharmacology. The retatrutide titration schedule is designed to produce a sustainable deficit, not an aggressive one.

6. The endpoints the stack rationale does and doesn't have data for

• Yes (independent data): Retatrutide produces ~24% total weight loss at 48 weeks (Jastreboff 2023).
• Yes (independent data): Tesamorelin produces ~15% VAT reduction at 26 weeks (Falutz 2010, Stanley 2014).
• Yes (independent data): GHRH-driven IGF-1 elevation supports lean-mass preservation during caloric deficit in resistance-training populations.
• Limited: No published RCT testing the combined stack for body recomposition endpoints. The case is extrapolation from independent monotherapy datasets.
• Unknown: Long-term (>1 year) combined-stack effects, optimal dose ratios, sequencing strategies (concurrent vs phased).

7. Alternative and adjacent peptide additions

Researchers commonly ask about adding other peptides to the body recomp stack. The honest answers:

• BPC-157: No body-composition evidence base. It's a tissue-repair peptide; adds nothing to recomp specifically. Useful only if there's a concurrent injury.
• MOTS-c: Mitochondrial-derived peptide with metabolic-signalling effects. Some mechanistic plausibility for adding to recomp protocols; no direct human RCT data on body composition.
• NAD+ / NMN: Mitochondrial coenzyme support. No direct body-composition data; commonly added for energy support during caloric deficit.
• Ipamorelin / CJC-1295: Alternative GH-axis peptides. Often substituted for Tesamorelin in research protocols where cost is the gating factor. The dose-response data on these is less robust than the Tesamorelin Falutz/Stanley dataset.

8. UAE supply context

UAE researchers running body-recomp stack protocols benefit from co-ordered, lot-matched supply. REVIVE LAB UAE supplies both Retatrutide UAE (5 mg, 10 mg) and Tesamorelin UAE (5 mg, 10 mg) with shared lot-level HPLC certificate of analysis. Same-day Dubai dispatch on orders before 3 PM, 24-hour delivery across the seven emirates. The full UAE stack of peptides UAE is available in one consolidated order to simplify protocol logistics.

9. The summary

• GLP-1 monotherapy loses 25-40% of weight as lean mass — that's the problem the stack addresses.
• GHRH analogues drive endogenous GH pulses → IGF-1 support for lean mass + VAT-preferential lipolysis.
• Dose pairing in research-protocol literature: Retatrutide titrated to 4-8 mg/week + Tesamorelin 2 mg/day SC bedtime.
• No documented PK interaction. Same-day admin OK. Bedtime timing for Tesamorelin matters (aligns with natural GH pulse window).
• Stack doesn't replace protein intake or resistance training — both are required for lean-mass preservation regardless of pharmacology.
• Both peptides available as Retatrutide UAE and Tesamorelin UAE via REVIVE LAB in HPLC-verified vials with lot-level COA.